MARKET

INDP

INDP

Indaptus Therapeutics Inc
NASDAQ
2.610
-0.160
-5.78%
After Hours: 2.600 -0.01 -0.38% 19:49 07/24 EDT
OPEN
2.880
PREV CLOSE
2.770
HIGH
2.880
LOW
2.565
VOLUME
55.68K
TURNOVER
--
52 WEEK HIGH
12.03
52 WEEK LOW
0.9200
MARKET CAP
347.76M
P/E (TTM)
-0.1551
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INDP last week (0713-0717)?
Weekly Report · 5d ago
Weekly Report: what happened at INDP last week (0706-0710)?
Weekly Report · 07/13 10:06
Weekly Report: what happened at INDP last week (0629-0703)?
Weekly Report · 07/06 10:09
Weekly Report: what happened at INDP last week (0622-0626)?
Weekly Report · 06/29 10:05
Indaptus Therapeutics Files Prospectus Related To The Resale By The Selling Stockholders Of Up To 18.86M Shares Of Common Stock
Benzinga · 06/26 21:26
INDAPTUS THERAPEUTICS INC - FILES FOR RESALE BY THE SELLING STOCKHOLDERS OF UP TO 18.86 MLN SHARES OF COMMON STOCK - SEC FILING
Reuters · 06/26 21:23
Indaptus Therapeutics Announces Private Placement of Common Stock
TipRanks · 06/24 20:39
Indaptus Therapeutics Entered Stock Sale Agreement To Sell 20M Shares For $0.06/Share; Gross Proceeds Of $12M
Benzinga · 06/24 20:07
More
About INDP
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

Webull offers Indaptus Therapeutics Inc stock information, including NASDAQ: INDP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INDP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INDP stock methods without spending real money on the virtual paper trading platform.